Abstract
The prognostic relevance of CD5 expression in marginal zone lymphoma (MZL) remains poorly characterized. We aimed to compare baseline characteristics and outcomes of patients with CD5(+) MZL and CD5(-) historical matched controls. We hypothesized that patients with CD5(+) MZL may have similarities to other CD5(-) expressing B-cell lymphomas, which may be informative when considering alternative therapeutic approaches for this MZL subgroup. We retrospectively analyzed 64 patients with CD5(+) MZL and 137 CD5(-) MZL controls matched on age at diagnosis and sex. The CD5(+) and CD5(-) cases did not differ in terms of mucosa assiociated lymphoid tissue (MALT)-lymphoma International Prognostic Index or incidence of nodal involvement. Bone marrow involvement was significantly more frequent in CD5(+) patients than in CD5(-) patients (67.5% vs 47.2%; P = .048). Mutated immunoglobulin heavy chain variable region gene was more common in CD5(+) patients (80.0%) than CD5(-) patients (64.0%), but this association was not significant (P = .327). Overall survival was calculated until death from any cause, disease-specific survival until lymphoma-related death, and time from diagnosis to first treatment was calculated either considering all interventions or only systemic treatments. None of these outcomes were associated with CD5 expression.